US Pharmacopeia (USP), an independent scientific organization, announced on March 16, 2022 that its USP Medicine Supply Vulnerability Insights Series reveals vulnerabilities in global API supply.
The first conclusion released from the Series discusses the significance of large Indian facilities in the manufacturing of API. There are currently 114 facilities in India with more than 30 active US-approved API products, which is significantly higher than any other region of the world.
